How will Cingulate Inc. secure the $7.0 million needed by Q2 2026, as disclosed in its November 13, 2025 10-Q?

Cingulate Inc.'s November 13, 2025 10-Q filing indicates that the company will need to raise approximately $7.0 million in additional capital to advance commercialization efforts for its lead asset, CTx-1301, through its Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026.1

As of September 30, 2025, Cingulate reported cash and cash equivalents of approximately $6.1 million.1 The company has historically operated with losses and negative cash flows, relying on external capital to fund its operations as a pre-revenue entity.1

Subsequent to September 30, 2025, and prior to the 10-Q filing date, Cingulate secured some additional funding:

• Debt Issuance: On November 7, 2025, the company entered into a note purchase agreement with Avondale Capital, LLC, receiving $6.0 million in cash from an unsecured promissory note.1
• Equity Sales: Cingulate also generated approximately $2.65 million from the sale of common stock under an At-The-Market (ATM) Agreement and a 2025 LP Purchase Agreement.1

While these funds, totaling approximately $8.65 million, were expected to satisfy capital needs into the second quarter of 2026 under the company's then-current business plan, the 10-Q explicitly states that an additional $7.0 million is still required specifically for commercialization activities leading up to the PDUFA date.1 The company's management is evaluating various strategies to obtain this additional funding, including further equity offerings, debt issuance, collaborations with other companies, or other strategic transactions.1 The 10-Q does not detail a secured plan for this specific $7.0 million, but rather outlines the anticipated need and potential avenues for financing.

Review the "Risk Factors" section of Cingulate's latest 10-K for detailed discussions on financing risks and potential impacts of failing to secure additional capital.